Skip to main content
SpringerLink
Log in

Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The aim of this study was to investigate several bone markers in Non-Small Cell Lung (NSCLC) and Small Cell Lung (SCLC) patients experiencing or not secondary bony disease. Fasting serum levels of bone formation, bone resorption, and osteoclastogenesis markers were determined in 22 NSCLC patients with bone metastases, 18 without bone metastasis, and 28 SCLC patients. A total of 29 healthy volunteers were also included in the study. Decreased osteocalcin (OC) serum levels and increased osteopontin and ligand of the receptor of nuclear factor kB (RANKL) serum levels were detected in NCSLC patients with bone metastases while increased C-terminal cross-linking telopeptide of type I collagen and increased RANKL/OPG (osteoprotegerin) ratio were detected in SCLC patients. Increased serum levels of OPG were observed in all lung cancer patients. OPG may be actively involved in the development of lung cancer metastasis. Furthermore, OC, OPN, and RANKL in NSCLC and CTX and RANKL in SCLC patients may also have a broader role in the pathogenesis and spread of lung cancer. They also provide useful information in identifying the group of patients that may benefit from a more rigorous treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93. doi:10.1038/nrc867.

    Article  CAS  PubMed  Google Scholar 

  2. Yin JJ, Pollock CB, Kelly K. Mechanisms of cancer metastasis to the bone. Cell Res. 2005;15:57–62. doi:10.1038/sj.cr.7290266.

    Article  CAS  PubMed  Google Scholar 

  3. Cho NH, et al. MMP expression profiling in recurred stage IB lung cancer. Oncogene. 2004;23:845–51. doi:10.1038/sj.onc.1207140.

    Article  CAS  PubMed  Google Scholar 

  4. Takenaka K, et al. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer. 2004;40:1617–23. doi:10.1016/j.ejca.2004.02.028.

    Article  CAS  PubMed  Google Scholar 

  5. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res. 2001;7:404060–6.

    Google Scholar 

  6. Tanko LB, Karsdal MA, Christiansen C, Leeming DJ. Biochemical approach to the detection and monitoring of metastatic bone disease: what do we know and what questions need answers? Cancer Metastasis Rev. 2006;25:659–68. doi:10.1007/s10555-006-9024-0.

    Article  PubMed  Google Scholar 

  7. Papotti M, et al. Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol. 2006;24:4818–24. doi:10.1200/JCO.2006.06.1952.

    Article  CAS  PubMed  Google Scholar 

  8. Kim K, et al. The role of whole body bone scan in bronchogenic carcinoma. Yonsei Med J. 1984;25:11–7.

    CAS  PubMed  Google Scholar 

  9. Perez DJ, et al. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet. 1983;2:613–6. doi:10.1016/S0140-6736(83)90692-X.

    Article  CAS  PubMed  Google Scholar 

  10. Ebert W, Muley T, Herb KP, Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res. 2004;24:3193–201.

    CAS  PubMed  Google Scholar 

  11. Lote K, Walloe A, Bjersand A. Bone metastasis. Prognosis, diagnosis and treatment. Acta Radiol Oncol. 1986;25:227–32. doi:10.3109/02841868609136410.

    Article  CAS  PubMed  Google Scholar 

  12. Coleman RE. Conclusion: bone markers in metastatic bone disease. Cancer Treat Rev. 2006;32(Suppl 1):27–8. doi:10.1016/S0305-7372(06)80007-1.

    Article  PubMed  Google Scholar 

  13. Arai Y, Takeuchi H, Oishi K, Yoshida O. Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate. 1992;20:169–77. doi:10.1002/pros.2990200302.

    Article  CAS  PubMed  Google Scholar 

  14. O’Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev. 2003;14:479–88. doi:10.1016/S1359-6101(03)00055-8.

    Article  PubMed  Google Scholar 

  15. Garnero P, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000;82:858–64. doi:10.1054/bjoc.1999.1012.

    Article  CAS  PubMed  Google Scholar 

  16. Oremek GM, Weis A, Sapoutzis N, Sauer-Eppel H. Diagnostic value of bone and tumour markers in patients with malignant diseases. Anticancer Res. 2003;23:987–90.

    CAS  PubMed  Google Scholar 

  17. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000;88:2919–26. doi:10.1002/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z.

    Article  CAS  PubMed  Google Scholar 

  18. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490–5. doi:10.1001/jama.292.4.490.

    Article  CAS  PubMed  Google Scholar 

  19. Theoleyre S, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457–75. doi:10.1016/j.cytogfr.2004.06.004.

    Article  CAS  PubMed  Google Scholar 

  20. Mountzios G, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 2007;46:221–9. doi:10.1080/02841860600635870.

    Article  CAS  PubMed  Google Scholar 

  21. Grimaud E, et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol. 2003;163:2021–31.

    CAS  PubMed  Google Scholar 

  22. Terpos E, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102:1064–9. doi:10.1182/blood-2003-02-0380.

    Article  CAS  PubMed  Google Scholar 

  23. Jung K, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer. 2004;111:783–91. doi:10.1002/ijc.20314.

    Article  CAS  PubMed  Google Scholar 

  24. Cross SS, et al. Osteoprotegerin (OPG)—a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118:1901–8. doi:10.1002/ijc.21606.

    Article  CAS  PubMed  Google Scholar 

  25. Leeming DJ, et al. The relative use of eight collagenous and non-collagenous markers for diagnosis of skeletal metastases in breast, prostate, or lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2006;15:32–8. doi:10.1158/1055-9965.EPI-05-0492.

    Article  CAS  PubMed  Google Scholar 

  26. Terpos E, et al. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer. 2003;106:455–7. doi:10.1002/ijc.11247.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Unit, Third Department of Medicine, Building Z, Sotiria General Hospital, Athens University School of Medicine, Mesogion 152, Athens, 115 27, Greece

    Eleni M. Karapanagiotou, Kalliopi D. Dilana, Christina Alamara, Ioannis Gkiozos & Kostas N. Syrigos

  2. Department of Medical Research, 251 General Air Force Hospital, Athens, Greece

    Evangelos Terpos

  3. Medical Oncology Unit, Laiko General Hospital, Athens University, School of Medicine, Athens, Greece

    Aris Polyzos

Authors
  1. Eleni M. Karapanagiotou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evangelos Terpos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kalliopi D. Dilana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christina Alamara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ioannis Gkiozos
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aris Polyzos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kostas N. Syrigos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eleni M. Karapanagiotou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Karapanagiotou, E.M., Terpos, E., Dilana, K.D. et al. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol 27, 332–338 (2010). https://doi.org/10.1007/s12032-009-9214-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-009-9214-z

Keywords

Search

Navigation